- Home
- MPLT vs GENI Comparison
MPLT vs GENI Comparison
Compare MPLT & GENI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPLT | GENI |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MPLT | GENI |
|---|---|---|
| Price | $7.78 | $6.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 21 |
| Target Price | ★ $26.54 | $10.83 |
| AVG Volume (30 Days) | 420.3K | ★ 7.7M |
| Earning Date | 12-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $51.71 |
| Revenue Next Year | N/A | $28.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $3.83 |
| 52 Week High | $40.43 | $12.39 |
Technical Indicators
Market Signals| Indicator | MPLT | GENI |
|---|---|---|
| Relative Strength Index (RSI) | 22.05 | 43.15 |
| Support Level | N/A | $5.98 |
| Resistance Level | $20.46 | $6.74 |
| Average True Range (ATR) | 0.58 | 0.37 |
| MACD | -0.04 | 0.08 |
| Stochastic Oscillator | 11.14 | 47.69 |
Price Performance
Historical ComparisonAbout MPLT MapLight Therapeutics Inc.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
About GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas: Sports Technology and Services; Betting Technology, Content, and Services; and Media Technology, Content, and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content, and Services division. Geographically, the company derives a majority of its revenue from America.